[Single cardiac troponin T measurement predicts risk for adverse outcome in decompensated heart failure]

Manoel Domingos C Oliveira1, Juliana Alvares, Maria Consolação V Moreira

  • 1Hospital Felicio Rocho, Belo Horizonte, MG, Brasil. manoeldomingos@felicoop.org.br

Insights

Elevated cardiac troponin T (TnT) levels upon hospital admission for decompensated heart failure (HF) indicate a higher risk of adverse outcomes. This biomarker aids in early risk stratification for long-term mortality in HF patients.

Area of Science:

  • Cardiology
  • Biomarkers
  • Heart Failure Research

Context:

  • Heart failure (HF) involves myocardial injury, evidenced by troponin release.
  • Cardiac troponin T (TnT) elevation suggests ongoing myocardial damage in HF patients.

Purpose:

  • To investigate the prognostic value of serum cardiac troponin T (TnT) levels at hospital admission.
  • To correlate TnT levels with prognosis in patients hospitalized for decompensated HF.

Summary:

  • A study of 79 decompensated HF patients found high TnT levels (>0.02 ng/ml) in 46.84%.
  • Higher TnT levels correlated with increased mortality (p=0.004) and a trend towards higher mortality in multivariate analysis (HR=2.64, p=0.07).
  • Despite not being an independent predictor in multivariate analysis, TnT showed prognostic value.

Impact:

  • Serum TnT measurement at admission can predict adverse outcomes in decompensated HF.
  • This finding supports the early stratification of long-term morbimortality risk in HF patients.
  • Highlights the role of TnT as a prognostic biomarker in heart failure management.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...